Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor (original) (raw)
Thromb Haemost 1981; 46(03): 662-665
DOI: 10.1055/s-0038-1653443
Schattauer GmbH Stuttgart
C Korninger
The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
D Collen
The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
Further Information
Publication History
Received 03 June 1981
Accepted 03 September 1981
Publication Date:
05 July 2018 (online)
Summary
Human extrinsic plasminogen activator (EPA), highly purified from a melanoma cell culture fluid is inactivated in human plasma with a half-life (t ½) of 90–105 min. Gel filtration on Ultrogel AcA 34 of mixtures of 125I-labeled EPA and human plasma, incubated at 37°C, revealed the progressive formation of two radioactive components, one with an apparent Mr of 150,000 and one eluting at the void volume. The component with an Mr of 150,000 was identified as consisting at least in part of EPA-α2-antiplasmin complex since: 1) it reacted with antibodies against α2-antiplasmin, but not with antibodies against the other known plasma protease inhibitors, and 2) formation of this component was strongly reduced in plasma specifically depleted in α2-antiplasmin or when the active site of EPA was blocked. The component eluting at the void volume was identified as consisting at least in part of EPA-α2-macroglobulin complex since: 1) it only reacted with antibodies against these two proteins and 2) was not formed in plasma depleted in α2-macroglobulin or when the active site of EPA was blocked.
In purified systems α2-antiplasmin inhibited one-chain EPA with a rate constant of 60 M-1s-1 and two-chain EPA with a rate constant of 130 M-1s-1, which corresponds to a t ½ in plasma of 180 min or 90 min, respectively. α2-Macroglobulin inhibited one-chain EPA with a rate constant of 15 M-1s-1 and two-chain EPA with a rate constant of 30 M-1s-1, which corresponds to a t ½ plasma of 4 or 2 hrs.
All these findings taken together indicate that EPA is slowly neutralized in human plasma primarily by α2-antiplasmin and to a lesser extent by α2-macroglobulin. There appears to be no specific inhibitor in human plasma, which would inactivate EPA either rapidly or to a significant extent.
Keywords
Extrinsic (tissue-type) plasminogen activator - α2-antiplasmin - α2-macroglobulin - Antiactivator
References
- 1 Aoki N, von Kaulla KN. Human serum plasminogen antiactivator: its distinction from antiplasmin. Am J Physiol 1971; 220: 1137-1145
- 2 Beattie AG, Ogston D, Bennett B, Douglas AS. Inhibitors of plasminogen activation in human blood. Br J Haemat 1976; 32: 135-143
- 3 Gurewich V, Hyde E, Lipinski B. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs. Blood 1975; 46: 555-565
- 4 Brakman P, Mohler ER, Astrup T. A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator induced fibrinolysis. Scand J Haematol 1966; 3: 389-398
- 5 Pandolfi M, Nilsson IM, Hedner U. Bilateral occlusion of the retinal veins in a patient with inhibition of fibrinolysis. Ann Ophtalmol 1970; 2: 481-485
- 6 Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
- 7 Moroi M, Aoki N. Isolation and characterization of alpha 2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis J Biol Chem 1976; 251: 5956-5965
- 8 Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553
- 9 Paraskevas M, Nilsson IM, Martinsson G. A method for determining serum inhibitors of plasminogen activation. Scand J Clin Lab Invest 1962; 14: 138-144
- 10 Bennett NB. A method for the quantitative assay of inhibitor of plasminogen activation in human serum. Thrombos Diathes haemorrh 1967; 17: 12-22
- 11 Clemmensen I, Christensen F. Inhibition of urokinase by complex formation with human α2-antitrypsin. Biochim Biophys Acta 1976; 429: 591-599
- 12 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
- 13 Rijken DC. Biochemical and immunological characterization of plasminogen activator from human tissue. In: “Progress in Chemical Fibrinolysis and Thrombolysis, Vol.4”. Davidson JF, Cepelak V, Samama MM, Desnoyers PC. (eds) p 349-354 Churchill Livingstone; Edinburgh: 1979
- 14 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
- 15 McFarlane AG. Efficient trace-labelling of proteins with iodine. Nature 1958; 182: 53
- 16 Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
- 17 Harpel PC. Studies on human plasma α2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure J Exp Med 1973; 138: 508-517
- 18 Ganrot PO. Determination of α2-macroglobulin as a trypsin esterase. Clin Chim Acta 1966; 14: 493-501
- 19 Alkjaersig N, Fletcher A. Metabolism of urokinase. In: »Thrombosis and Urokinase«. Paoletti R, Sherry S. eds Academic Press; London: 1977. p 129-141
- 20 Kominger C, Stassen JM, Collen D. Turnover of human extrinsic plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 659-662